A detailed history of Jpmorgan Chase & CO transactions in Annexon, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,686,372 shares of ANNX stock, worth $12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,686,372
Previous 959,648 75.73%
Holding current value
$12 Million
Previous $6.88 Million 20.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$4.33 - $6.79 $3.15 Million - $4.93 Million
726,724 Added 75.73%
1,686,372 $8.26 Million
Q1 2024

May 10, 2024

BUY
$4.03 - $7.81 $3.75 Million - $7.26 Million
930,063 Added 3143.7%
959,648 $6.88 Million
Q4 2023

Feb 12, 2024

SELL
$1.63 - $4.63 $16,355 - $46,457
-10,034 Reduced 25.33%
29,585 $134,000
Q3 2023

Nov 14, 2023

BUY
$2.13 - $3.84 $3,148 - $5,675
1,478 Added 3.88%
39,619 $93,000
Q2 2023

Aug 11, 2023

BUY
$2.1 - $6.37 $76,488 - $232,014
36,423 Added 2120.08%
38,141 $134,000
Q1 2023

May 11, 2023

SELL
$3.74 - $7.46 $112,214 - $223,829
-30,004 Reduced 94.58%
1,718 $6,000
Q4 2022

Feb 13, 2023

BUY
$4.56 - $6.61 $26,019 - $37,716
5,706 Added 21.93%
31,722 $164,000
Q3 2022

Nov 14, 2022

SELL
$3.75 - $6.63 $627,063 - $1.11 Million
-167,217 Reduced 86.54%
26,016 $160,000
Q2 2022

Aug 11, 2022

BUY
$2.11 - $4.06 $215,521 - $414,700
102,143 Added 112.13%
193,233 $728,000
Q1 2022

May 11, 2022

BUY
$2.73 - $11.94 $47,911 - $209,547
17,550 Added 23.86%
91,090 $249,000
Q4 2021

Feb 10, 2022

BUY
$11.49 - $22.0 $28,299 - $54,186
2,463 Added 3.47%
73,540 $845,000
Q3 2021

Nov 12, 2021

BUY
$16.35 - $23.4 $1.16 Million - $1.66 Million
71,077 New
71,077 $1.32 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $338M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.